ArticleVeterinary clinical pathology2026
Analytical Validation of an Automated Point-of-Care Immunoassay for the Measurement of Canine Pancreatic Lipase Immunoreactivity Concentration (Vcheck cPL 2.0).
Article in Veterinary clinical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic lipase assays are commonly utilized in the diagnostic approach to suspected pancreatitis in dogs. While a previously available point-of-care assay for the quantification of canine pancreatic lipase immunoreactivity (Vcheck cPL 1.0) performed sub-optimally, the updated version (Vcheck cPL 2.0) lacks independent validation.
objectiveTo evaluate the analytic validity of the Vcheck cPL 2.0 assay.
methodsLinearity was assessed via dilutional parallelism. Intra- and inter-assay variability were assessed by calculating coefficients of variation across replicates on the same day and across consecutive days, respectively. Interference studies were performed to assess the effects of bilirubin, hemoglobin, and lipid presence in test samples on assay performance.
resultsLinearity appeared within target parameters at pancreatic lipase concentrations up to ~800 md/dL (mean O/E ratio: 0.968 ± 0.104) but was unacceptable at pancreatic lipase concentrations > 2000 mg/dL (mean O/E ratio: 1.432 ± 0.178). Intra-assay precision (median coefficient of variation 7.2%) was acceptable; however, inter-assay precision was sub-optimal (coefficient of variation > 10%) in 50% of samples analyzed. Variable precision may result in different diagnostic interpretations. Icterus and lipemia did not impact assay results. However, hemolysis, when severe (375-500 mg/dL), may impact test results (p < 0.005).
conclusionsThe Vcheck cPL 2.0 shows improved precision compared to previous versions. Linearity was unacceptable at higher pancreatic lipase concentrations and hemolysis may impact Vcheck cPL 2.0 assay results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.